FLT3 and acute myeloid leukemia: (49) successfully engineered CAR-T cells targeting FMS-like tyrosine kinase 3 (FLT3) to treat the high-risk FLT3-ITD+ AML patients synergistically with the FLT3 inhibitor crenolanib.